Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome

Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Neurogastroenterology and Motility (Impact Factor: 3.42). 11/2009; 22(5):512-9, e114-5. DOI: 10.1111/j.1365-2982.2009.01427.x
Source: PubMed

ABSTRACT The profile of intestinal organic acids in irritable bowel syndrome (IBS) and its correlation with gastrointestinal (GI) symptoms are not clear. We hypothesized in this study that altered GI microbiota contribute to IBS symptoms through increased levels of organic acids.
Subjects were 26 IBS patients and 26 age- and sex-matched controls. Fecal samples were collected for microbiota analysis using quantitative real-time polymerase chain reaction and culture methods, and the determination of organic acid levels using high-performance liquid chromatography. Abdominal gas was quantified by image analyses of abdominal X-ray films. Subjects completed a questionnaire for GI symptoms, quality of life (QOL) and negative emotion.
Irritable bowel syndrome patients showed significantly higher counts of Veillonella (P = 0.046) and Lactobacillus (P = 0.031) than controls. They also expressed significantly higher levels of acetic acid (P = 0.049), propionic acid (P = 0.025) and total organic acids (P = 0.014) than controls. The quantity of bowel gas was not significantly different between controls and IBS patients. Finally, IBS patients with high acetic acid or propionic acid levels presented with significantly worse GI symptoms, QOL and negative emotions than those with low acetic acid or propionic acid levels or controls.
These results support the hypothesis that both fecal microbiota and organic acids are altered in IBS patients. A combination of Veillonella and Lactobacillus is known to produce acetic and propionic acid. High levels of acetic and propionic acid may associate with abdominal symptoms, impaired QOL and negative emotions in IBS.

  • Source
    • "Although it is unclear how these molecules influence central neurotransmission, it is possible that they can alter the central levels of neurotransmitters in the brain, leading to behavioral changes (Swain, 2006). Support for the premise that the intestinal microbiota can influence behavior comes from studies that have found an association between high levels of self-reported anxiety and elevated fecal concentrations of propionic acid (Tana et al., 2010) as well as the findings that commensal lactobacilli and bifidobacteria produce gammaaminobutyric acid (Barrett, Ross, O'Toole, Fitzgerald, & Stanton , 2012), an amino acid neurotransmitter with anxiolytic properties . Gut bacteria also produce serotonin (5-HT), dopamine (D), noradrenaline (NA), and acetylcholine (ACh). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Liver disease affects over 25 million people in the United States and, despite advances in medical management resulting in increased survival, a majority of these individuals report multiple co-occurring symptoms that severely impair functioning and quality of life. The purpose of this review is to (1) propose defining these co-occurring symptoms as a symptom cluster of chronic liver disease (CLD), (2) discuss putative underlying biological mechanisms related to CLD, including the liver-gut-brain axis and influence of the microbiome, and (3) discuss the implications for biobehavioral research in this patient population. Biobehavioral research focusing on the interrelated, and possibly synergistic, mechanisms of these symptoms may lead to the development and testing of targeted symptom management interventions for improving function and quality of life in this growing patient population.
    Biological Research for Nursing 07/2014; 17(2). DOI:10.1177/1099800414541541 · 1.34 Impact Factor
  • Source
    • "DGGE = Denaturing Gradient Gel Electrophoresis; GC = Guanine-Cytosine; IBS = irritable bowel syndrome; IBS-C = constipation-predominant irritable bowel syndrome; IBS-D = diarrhoea-predominant-irritable bowel syndrome; IBS-M = mixed-habit irritable bowel syndrome; N. = number; PCR = polymerase chain reaction; qPCR = quantitative polymerase chain reaction; RT-PCR-DGGE = realtime-polymerase chain reaction-denaturing gel gradient electrophoresis; 16S rDNA = 16S ribosomal DNA; 16SrRNA = 16S ribosomal RNA;" = increased; # = decreased. compounds [90] [91] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract The gastrointestinal tract is a natural reservoir of microbiota. The gut is germ-free at birth, but rapidly becomes host to various bacteria establishing a progressively mutual relationship. The composition of gut microbiota is individual-specific and depends on the genotype of the host and environmental factors. Novel techniques have been used to characterize gastrointestinal microbiota, including genomic approaches. The bacterial profile shows that dominant and minor phyla are present in the gastrointestinal tract. From the proximal to the distal segments of the gut the bacterial density gradually increases, reaching an estimated 10(11) to 10(12) bacteria per gram of colonic content. Dynamic interactions between gut and microbiota play a physiological role in metabolic, protective and structural functions, while dysbiosis contributes to several diseases. Microbiota appear to play a role in IBS, where qualitative and quantitative changes of bacteriaoccur in IBS subtypes. Initial therapeutic approaches in IBS have focused on microbiota. The relationship between perturbations of the microbiota, mucosal inflammation and IBS remains to be further investigated.
    Scandinavian Journal of Gastroenterology 09/2013; 48(9):995-1009. DOI:10.3109/00365521.2013.799220 · 2.33 Impact Factor
  • Source
    • "GIT symptoms can include dyspepsia, epigastric pain and burning, bloating, early satiety, nausea and belching, mucosal ulceration and altered bowel habits (constipation/ diarrhoea). In addition to analgesic and anti-inflammatory medicines inducing such GIT symptoms, altered GIT microbial growth trends may also contribute (Tana et al. 2010). We have recently reported that administration of GLM extract (3,000 mg/day) to OA patients significantly improved GIT symptoms, concurrent with significant improvement in knee pain, stiffness and function (Coulson et al. 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: To investigate how changes in the gastrointestinal tract (GIT) microbiota profile may influence nutraceutical efficacy in osteoarthritis (OA) and allow the formulation of a hypothesis that explains in part the inconsistent and contentious findings from OA clinical studies with green-lipped mussel (GLM) and glucosamine. METHODS: A non-blinded randomised clinical trial was conducted with 38 subjects diagnosed with knee OA. Each participant received either 3,000 mg/day of a whole GLM extract or 3,000 mg/day of glucosamine sulphate (GS), p.o. for 12 weeks. Faecal microbial analyses were carried out after collecting stools at T (0) and T (12) weeks. Additional pharmacometric measures were obtained from changes in arthritic scores in the Western Ontario McMaster Universities Arthritis Index (WOMAC) and the Lequesne algofunctional indices and the Gastrointestinal Symptom Rating Scale (GSRS). An intention-to-treat analysis was employed and participant data collected at T (0), T (6) and T (12) weeks. RESULTS: There were no statistically significant changes in bacterial growth patterns determined by the Wilcoxon test. In both groups there was a trend towards a decrease in Clostridium and Staphylococcus species and increase in Lactobacillus, Streptococcus and Eubacterium species. In the GLM group Bifidobacterium tended to increase and Enterococcus and yeast species to decrease. The GS-treated group demonstrated a trend towards a decrease in Bacteroides and an increase in yeasts and Coliforms species, most notably Escherichia coli. We further confirm significant improvement (p < 0.05) in all OA outcome measures from T (0) to T (12) weeks for both the GLM and GS groups. The GSRS scores indicated that GIT function significantly improved over the 12 weeks duration with GLM and GS supplementation. CONCLUSION: Both GLM and GS reduced OA symptoms and non-significantly altered the gut microbiota profile from baseline. Changes in the microbiota profiles occurred in both treatment groups; the most notable being a reduction in the Clostridia sp. This study suggests that nutritional supplements such as GLM and GS may regulate some of the metabolic and immunological activities of the GIT microbiota. The decrease in Clostridia, a potent modulator of colonic Th17 and CD4+ regulatory T cells, was consistent with a decrease in inflammation; improved GSRS scores and OA symptoms for these OA participants. The GIT microbiota may be important factor in the first-pass metabolism of these nutraceuticals.
    Inflammopharmacology 07/2012; DOI:10.1007/s10787-012-0146-4
Show more